Better Therapeutics (Better Therapeutics) Pre-Tax Income : $-31.56 Mil (TTM As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Better Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Better Therapeutics's pretax income for the three months ended in Sep. 2023 was $-5.86 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2023 was $-31.56 Mil. Better Therapeutics's pretax margin was %.

During the past 4 years, Better Therapeutics's highest Pretax Margin was -32133.33%. The lowest was -77925.00%. And the median was -55029.17%.

Better Therapeutics Pre-Tax Income Historical Data

The historical data trend for Better Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Better Therapeutics Pre-Tax Income Chart

Better Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Pre-Tax Income

-5.78

-6.23

-40.49

-39.75

Better Therapeutics Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Pre-Tax Income	Get a 7-Day Free Trial									-11.40	-8.76	-9.36	-7.59	-5.86

Competitive Comparison of Better Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Better Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Better Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Better Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Better Therapeutics's Pre-Tax Income falls into.

Better Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Better Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-38.262	+	0	+	-1.491	+	0	+	0
	=	-39.75

Better Therapeutics's Pretax Income for the quarter that ended in Sep. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-5.341	+	0	+	-0.518	+	0	+	0
	=	-5.86

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.56 Mil.

Better Therapeutics (OTCPK:BTTX) Pre-Tax Income Explanation

Better Therapeutics's Pretax Margin for the quarter that ended in Sep. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-5.859	/	0
	=	%

During the past 4 years, Better Therapeutics's highest Pretax Margin was -32133.33%. The lowest was -77925.00%. And the median was -55029.17%.

Better Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Better Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Better Therapeutics (Better Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Better Therapeutics Inc (OTCPK:BTTX) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

548 Market Street, Suite 49404, San Francisco, CA, USA, 94104

Website

https://www.bettertx.com

Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.

Executives

Elder Granger	director	5176 S. LEWISTON WAY, CENTENNIAL CO 80015
Mark A. Berman	officer: Chief Medical Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Geoffrey M. Parker	director	15 RIORDAN PLACE, MENLO PARK CA 94025
Frank Karbe	director, officer: See Remarks	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David P Perry	director, 10 percent owner, officer: See Remarks	1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Andrew J. Armanino	director	C/O CALIFORNIA BANCORP, 1300 CLAY STREET, FIFTH FLOOR, OAKLAND CA 94612
Georgianna Maule-ffinch 2015 Trust	10 percent owner	C/O BETTER THERAPEUTICS, INC., 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Mark Heinen	officer: See Remarks	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Risa J Lavizzo-mourey	director	GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE ST., CHICAGO IL 60661
Kevin J Appelbaum	director, 10 percent owner, officer: Chief Executive Officer	4160 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Suying Liu	director	311 WEST 43RD STREET, 12TH FLOOR, NEW YORK NY 10036
Justin Zamirowski	officer: Chief Commercial Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Kristin Wynholds	officer: Chief Product Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Richard H Carmona	director	1221 BROADWAY, OAKLAND CA 94612
David P. Perry 2015 Trust	10 percent owner	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104